MNTA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MNTA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Momenta Pharmaceuticals's book value per share for the quarter that ended in Jun. 2020 was $3.33.
During the past 12 months, Momenta Pharmaceuticals's average Book Value Per Share Growth Rate was 5.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -10.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -0.10% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 4.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Momenta Pharmaceuticals was 54.30% per year. The lowest was -27.70% per year. And the median was 6.30% per year.
Momenta Pharmaceuticals's current price is $52.48. Its book value per share for the quarter that ended in Jun. 2020 was $3.33. Hence, today's PB Ratio of Momenta Pharmaceuticals is 15.75.
During the past 13 years, the highest P/B Ratio of Momenta Pharmaceuticals was 15.00. The lowest was 1.44. And the median was 2.99.
Warning Sign:
Momenta Pharmaceuticals Inc stock PB Ratio (=15) is close to 10-year high of 15
The historical data trend for Momenta Pharmaceuticals's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momenta Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||||
Book Value per Share | Get a 7-Day Free Trial | 5.36 | 5.23 | 4.90 | 4.68 | 3.90 |
Momenta Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | |
Book Value per Share | Get a 7-Day Free Trial | 3.17 | 2.79 | 3.90 | 3.64 | 3.33 |
For the Drug Manufacturers - Specialty & Generic subindustry, Momenta Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Momenta Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Momenta Pharmaceuticals's PB Ratio falls into.
Momenta Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2019 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (454.46 | - | 0.00) | / | 116.46 | |
= | 3.90 |
Momenta Pharmaceuticals's Book Value Per Share for the quarter that ended in Jun. 2020 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (395.32 | - | 0.00) | / | 118.60 | |
= | 3.33 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Momenta Pharmaceuticals (NAS:MNTA) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of Momenta Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Bruce Downey | director | |
Alejandra Carvajal | officer: Chief Legal Officer | C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139 |
Jose-carlos Gutierrez-ramos | director | C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
Georges Gemayel | director | 550 HILLS DRIVE, BEDMINSTER NJ 07921 |
Elizabeth Stoner | director | C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142 |
Santiago Arroyo | officer: SVP, Chief Medical Officer | C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
Young Kwon | officer: Chief Financial & Bus. Officer | C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
Ian Fier | officer: Chief Mfg and Program Officer | C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
Jo Ann Beltramello | officer: Chief HR and Inf. Officer | C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142 |
Jane F Barlow | director | 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487 |
Anthony M. Manning | officer: Chief Scientific Officer | C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Donna Roy Grogan | director | 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633 |
Agnieszka Cieplinska | officer: Chief Accounting Officer (PAO) | C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142 |
Craig A Wheeler | director, officer: President & CEO |
From GuruFocus
By Marketwired Marketwired • 09-15-2020
By Marketwired Marketwired • 08-03-2020
By Marketwired Marketwired • 07-28-2020
By [email protected] insider • 07-02-2020
By Marketwired Marketwired • 05-07-2020
By Marketwired Marketwired • 12-24-2019
By [email protected] insider • 06-16-2020
By [email protected] insider • 02-12-2020
By PRNewswire PRNewswire • 09-26-2020
By PRNewswire PRNewswire • 08-19-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.